Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SVRA Savara Inc

Post-Market Trading 03-26 16:54:24 EDT

2.70

-0.07

-2.53%

盘后2.74

+0.04+1.48%

16:53 EDT

High2.79	Low2.68	Vol967.46K
Open2.79	D1 Closing2.77	Amplitude4.15%
Mkt Cap463.37M	Tradable Cap302.40M	Total Shares171.62M
T/O2.62M	T/O Rate0.86%	Tradable Shares112.00M
P/B2.32	ROE-47.95%	EPS-0.43
52wk High5.34	52wk Low2.26	P/E-6.35
Dividend0.00	Div.Yield0.00	ROA-26.39%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":2.7,"timestamp":1743019200000,"preClose":2.77,"halted":0,"volume":967455,"hourTrading":{"tag":"盘后","latestPrice":2.74,"preClose":2.7,"latestTime":"16:53 EDT","volume":51490,"amount":145652.517715,"timestamp":1743022428691},"delay":0,"floatShares":112000000,"shares":171618944,"eps":-0.425487,"marketStatus":"Post-Market Trading","change":-0.07,"latestTime":"03-26 16:54:22 EDT","open":2.79,"high":2.79,"low":2.675,"amount":2624010.78231,"amplitude":0.041516,"askPrice":2.74,"askSize":58,"bidPrice":2.53,"bidSize":12,"shortable":3,"etf":0,"ttmEps":-0.425487,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743033600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.77,"preHourTrading":{"tag":"盘前","latestPrice":2.76,"preClose":2.77,"latestTime":"08:57 EDT","volume":3293,"amount":9113.370255400001,"timestamp":1742993833871},"postHourTrading":{"tag":"盘后","latestPrice":2.74,"preClose":2.7,"latestTime":"16:53 EDT","volume":51490,"amount":145652.517715,"timestamp":1743022428691},"volumeRatio":0.408814,"impliedVol":0.4846,"impliedVolPercentile":0.316},"requestUrl":"/m/hq/s/SVRA/tweets","defaultTab":"tweets","newsList":[{"id":"2522353018","title":"BRIEF-Savara Enters Into Non-Dilutive Debt Financing For Up To $200M With Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522353018","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522353018?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:47","pubTimestamp":1743022024,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Enters Into Non-Dilutive Debt Financing For Up To $200M With Hercules CapitalMarch 26 (Reuters) - Savara Inc SVRA.O:SAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M WITH HER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q917T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","HTGC","SVRA","BK4139"],"gpt_icon":0},{"id":"2522835377","title":"Savara Files Biologics License Application to US FDA for Molbreevi to Treat Lung Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522835377","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522835377?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:44","pubTimestamp":1743021886,"startTime":"0","endTime":"0","summary":"Savara  said late Wednesday it has completed submission of a biologics license application to the US Food and Drug Administration for Molbreevi to treat autoimmune pulmonary alveolar proteinosis, a rare lung disease.Savara requested priority review, which, if granted, will shorten the FDA's review to six months from the standard 10 months following the regulator's acceptance of the application, Chief Executive Matt Pauls said in a statement. The company remains on track with its commercial preparations to support a possible launch of the drug in early 2026, he added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522585483","title":"Savara completes BLA submission to FDA for Molbreevi","url":"https://stock-news.laohu8.com/highlight/detail?id=2522585483","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522585483?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:11","pubTimestamp":1743019870,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA marks ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-completes-bla-submission-to-fda-for-molbreevi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-completes-bla-submission-to-fda-for-molbreevi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522330496","title":"BRIEF-Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522330496","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522330496?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:07","pubTimestamp":1743019678,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA3YKFVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522998330","title":"Savara Completes Submission of the Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (Apap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522998330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522998330?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA3YKFVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2522333010","title":"Savara Inc: Commercial Preparations Are on-Track to Support a Potential Launch in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2522333010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522333010?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA3YKFVL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522301243","title":"Savara Inc - to Submit Molbreevi Maa in Europe by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522301243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522301243?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA3YKFVL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2522353711","title":"Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522353711","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522353711?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"-- Priority Review Was Requested, Commercial Launch Preparations Underway --. LANGHORNE, Pa., March 26, 2025----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP.\"Submission of the BLA marks an important milestone for the Company and the aPAP community,\" said Matt Pauls, Chair and Chief Executive Officer, Savara. \"We believe this unprecedented body of data demonstrates MOLBREEVI improves pulmonary gas exchange and the clinical symptoms associated with this rare lung disease. As part of the submission, Priority Review was requested and, if granted, would shorten the FDA’s review to six months  following the Agency’s acceptance of the application. We look forward to continuing our dialogue with the FDA and extend our gratitude to the patients and physicians who participated in our clinical trials. Our commercial preparations are on-tra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-completes-submission-biologics-license-200500101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1481599808.USD","LU1487256676.USD","LU2463526074.USD","BK4585","BK4588","BK4136","PIM","LU1481600234.SGD","MAA","SVRA","IP","BK4215","BK4139"],"gpt_icon":0},{"id":"2521288795","title":"Savara Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521288795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521288795?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:01","pubTimestamp":1742558483,"startTime":"0","endTime":"0","summary":"Savara Inc  expected to post a loss of11cents a share - Earnings Preview Savara Inc SVRA.OQ SVRA.O is expected to show no change in quarterly revenue when it reports  results on March 24 (estimated) f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2520520888","title":"Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520520888","media":"Business Wire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520520888?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:05","pubTimestamp":1742213100,"startTime":"0","endTime":"0","summary":"-- Company to Host Industry Theater on aPAP with Two World-Renowned Experts --. LANGHORNE, Pa., March 17, 2025----Savara Inc.  , a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society  International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled \"Advances in Autoimmune Pulmonary Alveolar Proteinosis \" at the meeting.The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine on May 1, 2025. For more details about the ATS International Conference please visit their website.aPAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-present-data-phase-3-120500851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","SVRA","AFG","BK4117","BK4139","BK4107","ATS"],"gpt_icon":0},{"id":"2518244943","title":"Savara Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244943","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518244943?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:05","pubTimestamp":1741604737,"startTime":"0","endTime":"0","summary":"Savara Inc  expected to post a loss of11cents a share - Earnings Preview Savara Inc SVRA.OQ SVRA.O is expected to show no change in quarterly revenue when it reports  results on March 12 (estimated) f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL8N3PT0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2517150949","title":"Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2517150949","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517150949?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:54","pubTimestamp":1741269245,"startTime":"0","endTime":"0","summary":"Savara  said Thursday it has launched its aPAP ClearPath dried blood spot test in the US.The test is designed to help obtain a diagnosis of aPAP, a rare autoimmune lung disease, through a finger-prick blood sample, the company said.The DBS test has achieved 100% sensitivity and specificity in  a group of individuals with aPAP autoantibody status, Savara said.Shares were almost 2% higher in recent premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2517157843","title":"Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157843","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517157843?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:05","pubTimestamp":1741266300,"startTime":"0","endTime":"0","summary":"-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor  Autoantibodies in the Blood with Only a Finger Prick --. LANGHORNE, Pa., March 06, 2025----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot  Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample.Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli  of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granuloc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-u-launch-apap-130500207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0477156953.USD","LU0320765489.SGD","BK4139","LU0648001328.SGD","GM","LU0006061336.USD","LU0208291251.USD","LU1201861165.SGD","CLIA","BK4566","LU0345770993.USD","LU0345770308.USD","LU0070302665.USD","SVRA","BK4588","LU0072461881.USD","DBS","LU0130103400.USD","LU0980610538.SGD","LU0130517989.USD","BK4559","BK4099","BK4596","LU0130102774.USD","BK4574","LU0477156797.USD","BK4516","LU0130518102.USD","LU1201861249.SGD","BK4555","LU0211331839.USD","LU0648000940.SGD","BK4561","LU0162691827.USD"],"gpt_icon":0},{"id":"2517972669","title":"Savara Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517972669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517972669?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 19:02","pubTimestamp":1741172564,"startTime":"0","endTime":"0","summary":"Savara Inc  expected to post a loss of11cents a share - Earnings Preview Savara Inc SVRA.OQ SVRA.O is expected to show no change in quarterly revenue when it reports  results on March 7 (estimated) fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL5N3PO0VA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2516669026","title":"Savara Announces Participation in the Leerink Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516669026","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516669026?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 05:15","pubTimestamp":1741036500,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., March 03, 2025----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT.*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.Media and Investor Relations Contact Savara Inc.Temre Johnson, Executive Director, Corporate Affairsir@savarapharma.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-participation-leerink-global-211500578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","HCSG","BK4137","BK4139"],"gpt_icon":0},{"id":"2514328574","title":"Mastek In Receipt Of Administrative Warning Letter Issued By Securities And Exchange Board Of India","url":"https://stock-news.laohu8.com/highlight/detail?id=2514328574","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514328574?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 19:45","pubTimestamp":1740743143,"startTime":"0","endTime":"0","summary":"Feb 28 (Reuters) - Mastek Ltd ::*RECEIPT OF ADMINISTRATIVE WARNING LETTER ISSUED BY SECURITIES AND EXCHANGE BOARD OF INDIA  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 28-FEB-202510:58:44.05 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nRSDK058y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2514845838","title":"BUZZ-India's Mastek gains on $85 mln order wins","url":"https://stock-news.laohu8.com/highlight/detail?id=2514845838","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514845838?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 12:33","pubTimestamp":1740630792,"startTime":"0","endTime":"0","summary":"BUZZ-India's Mastek gains on $85 mln order wins** Mastek MAST.NS rises as much as 4.4% to 2,465 rupees** IT services co secures multiple contracts worth ~$85 mln from the UK public service department** More than 72,000 shares traded, near their 30-day moving avg** Stock rated \"buy\" on avg; median PT is 3,410 rupees - LSEG** MAST last up 0.6%, cutting YTD losses to 20.7%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3N3PI0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2511610429","title":"Savara Announces New Employment Inducement Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2511610429","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511610429?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 05:05","pubTimestamp":1739567100,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., February 14, 2025----Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.On February 12, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 97,500 shares of the Company’s common stock and restricted stock units  covering an aggregate of 82,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635 of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-employment-inducement-grant-210500557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","SVRA","USAW.SI","QID","NQmain","QLD","MNQmain","TQQQ","TSYW.SI","SQQQ","USJW.SI",".IXIC","NVIW.SI","BK4139"],"gpt_icon":1},{"id":"2511663047","title":"Master Tec Announces Acceptance Of Letter Of Award From Tenaga Nasional","url":"https://stock-news.laohu8.com/highlight/detail?id=2511663047","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511663047?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 18:46","pubTimestamp":1739529984,"startTime":"0","endTime":"0","summary":"Feb 14 (Reuters) - Master Tec Group Bhd ::*ACCEPTANCE OF LETTER OF AWARD FROM TENAGA NASIONAL*UNIT ACCEPTED LETTER OF AWARD ON FEB 10 FOR UNDERGROUND CABLE & CONDUCTORS*VALUE OF CONTRACT IS 107.8 MILL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nRSD4gLZKW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2509903053","title":"Positive Signs As Multiple Insiders Buy Savara Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2509903053","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509903053?lang=en_us&edition=full_marsco","pubTime":"2025-02-08 20:57","pubTimestamp":1739019423,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Savara Inc. , that sends out a positive message to the company's shareholders.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But on the other ha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-signs-multiple-insiders-buy-125703442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com;www.masttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0297},{"period":"3month","weight":-0.1344},{"period":"6month","weight":-0.3467},{"period":"1year","weight":-0.4253},{"period":"ytd","weight":-0.0977}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":-0.0408},{"period":"3month","weight":-0.043},{"period":"6month","weight":0.0055},{"period":"1year","weight":0.1071},{"period":"ytd","weight":-0.0181}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.121255},{"month":2,"riseRate":0.25,"avgChangeRate":-0.051283},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.01131},{"month":4,"riseRate":0.583333,"avgChangeRate":0.025179},{"month":5,"riseRate":0.75,"avgChangeRate":0.049473},{"month":6,"riseRate":0.5,"avgChangeRate":-0.036588},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.037047},{"month":8,"riseRate":0.5,"avgChangeRate":-0.004589},{"month":9,"riseRate":0.5,"avgChangeRate":0.004673},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.1617},{"month":11,"riseRate":0.5,"avgChangeRate":0.099362},{"month":12,"riseRate":0.583333,"avgChangeRate":0.241594}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction